Clinical Trial Update: Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy [Phase 2]

View source ↗

Summary

Phase 2 trial investigating natalizumab for focal epilepsy has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Focal Seizures
• Partial Seizures

Drugs mentioned

• Natalizumab (natalizumab)

Snippet

Sponsor: Biogen | Conditions: Epilepsy, Focal Seizures, Partial Seizures | Phase 2 | Status: COMPLETED | Results posted: 2021-04-27